About: Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
Creator	Wang, Yun Xu, Xinni Kwang Ong, Yew
Source	Medline; PMC
abstract	The coronavirus disease (COVID-19) pandemic has led to a global struggle to cope with the sheer numbers of infected persons, many of whom require intensive care support or eventually succumb to the illness. The outbreak is managed by a combination of disease containment via public health measures and supportive care for those who are affected. To date, there is no specific anti-COVID-19 treatment. However, the urgency to identify treatments that could turn the tide has led to the emergence of several investigational drugs as potential candidates to improve outcome, especially in the severe to critically ill. While many of these adjunctive drugs are being investigated in clinical trials, professional bodies have attempted to clarify the setting where the use of these drugs may be considered as off-label or compassionate use. This review summarizes the clinical evidence of investigational adjunctive treatments used in COVID-19 patients as well as the recommendations of their use from guidelines issued by international and national organizations in healthcare.
has issue date	2020-05-05(xsd:dateTime)
bibo:doi	10.1186/s40779-020-00251-x
bibo:pmid	32370766
has license	cc-by
sha1sum (hex)	6ab285e312929c605f0e0d6a8110a732a7d42b6b
schema:url	https://doi.org/10.1186/s40779-020-00251-x
resource representing a document's title	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines
has PubMed Central identifier	PMC7199873
has PubMed identifier	32370766
schema:publication	Mil Med Res
resource representing a document's body	covid:6ab285e312929c605f0e0d6a8110a732a7d42b6b#body_text
is schema:about of	named entity 'illness' named entity 'professional bodies' named entity 'identify' named entity 'disease' named entity 'turn' named entity 'support' named entity 'PATIENTS' named entity 'USE' named entity 'COVID-19 TREATMENT' named entity 'COPE' named entity 'TURN' named entity 'OUTBREAK' named entity 'HAVE' named entity 'INVESTIGATIONAL DRUGS' named entity 'LED' named entity 'BODIES' named entity 'INVESTIGATED' named entity 'off-label' named entity 'drugs' named entity 'intensive care' named entity 'supportive care' named entity 'clinical trials' named entity 'While' named entity 'pathogen' named entity 'case reports' named entity 'lopinavir' named entity 'Convalescent plasma' named entity 'cardiomyopathy' named entity 'HCQ' named entity 'HCQ' named entity 'lung disease' named entity 'convalescent plasma' named entity 'administrated' named entity 'control group' named entity 'Neutralizing antibody' named entity 'Middle East respiratory syndrome coronavirus' named entity 'clinical guidelines' named entity 'controlled trials' named entity 'Corticosteroids' named entity 'FDA' named entity 'umifenovir' named entity 'umbilical cord' named entity 'intubated' named entity 'anaemia' named entity 'viral RNA' named entity 'oxygen' named entity 'clinical outcome' named entity 'coagulation' named entity 'heparin' named entity 'HLA' named entity 'antivirals' named entity 'COVID' named entity 'HCQ' named entity 'meta-analysis' named entity 'HCQ' named entity 'HCQ' named entity 'pancreatitis' named entity 'renal failure' named entity 'COVID' named entity 'WHO' named entity 'transfusion' named entity 'Clostridiodes difficile' named entity 'HCQ' named entity 'potential treatments' named entity 'serum' named entity 'COVID-19' named entity 'HCQ' named entity '95% CI' named entity 'activated partial thromboplastin time' named entity 'SARS' named entity 'pharmaceutical company' named entity 'prolonged QT interval' named entity 'T-cell' named entity 'cardiotoxicity' named entity 'convalescent plasma' named entity 'COVID' named entity 'umifenovir' named entity 'chloroquine' named entity 'immunomodulation'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software